Genmab — Marts 2018
-
Spændende artikel om Novartis https://www.bloomberg.com/gadfly/articles/2018-03-27/novartis-glaxo-asset-un-swap-a-sign-of-things-to-come
-
Jeg ved ikke om de har flere MS drugs ? Men det virker til at være et vigtigt område for deres nye CEO https://www.weforum.org/agenda/2018/01/3-things-change-medicine-2018-big-data-healthcare/
-
yes, they are good in MS. They recently published some data on siponimod https://www.novartis.com/news/media-releases/phase-iii-data-lancet-show-novartis-siponimod-significantly-improves-outcomes-patients-secondary-progressive-ms , and this is from last year https://www.novartis.com/news/media-releases/novartis-confirms-leadership-multiple-sclerosis-ms-scientific-advancements-and
-
God fantasi: Novartis køber Gen for 20+bn usd. Sælger dara royalty + evt. De duo aftaler der er til jnj. Novartis bevarer Gen som en selvstændig afd. I Utrecht. Novartis sparer fremtidig royalty på Arzerra. Gen bliver så ikke selvstændig , knock your socks of company, 2025.
-
Solsen...Se 9.49
-
Japan's Takeda considering approach for British drugmaker Shire
https://uk.reuters.com/article/us-shire-m-a-takeda-pharma/japans-takeda-considering-approach-for-british-drugmaker-shire-idUKKBN1H4198 -
Ser ud til vi bryder 200 dages glidende gennemsnit i dag...
-
-
Bing bing bing
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind